Diaxonhit SA Share Price Other OTC
Equities
FR0004054427
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
24/06 | Proteomics International Laboratories Taps French Distributor for Diabetic Kidney Disease Test | MT |
08/05 | Eurobio Scientific: agreement with Myriad Genetics | CF |
Sales 2024 * | 138M 149M 12.47B | Sales 2025 * | 148M 160M 13.39B | Capitalization | 139M 150M 12.53B |
---|---|---|---|---|---|
Net income 2024 * | 9M 9.74M 814M | Net income 2025 * | 11M 11.91M 994M | EV / Sales 2024 * | 0.93 x |
Net cash position 2024 * | 9.9M 10.72M 895M | Net cash position 2025 * | 32.8M 35.51M 2.96B | EV / Sales 2025 * | 0.71 x |
P/E ratio 2024 * |
14.5
x | P/E ratio 2025 * |
11.4
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 51.91% |
Managers | Title | Age | Since |
---|---|---|---|
Denis Fortier
CEO | Chief Executive Officer | - | 19/17/19 |
Director of Finance/CFO | 43 | 01/22/01 | |
Cathie Marsais
COO | Chief Operating Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Denis Fortier
CEO | Chief Executive Officer | - | 19/17/19 |
Director/Board Member | 68 | 04/09/04 | |
Director/Board Member | 67 | 15/17/15 |
1st Jan change | Capi. | |
---|---|---|
+18.97% | 45.34B | |
+41.98% | 40.42B | |
-10.06% | 37.92B | |
+31.15% | 31.75B | |
-7.79% | 27.71B | |
+13.32% | 26.52B | |
+43.05% | 13.96B | |
+31.28% | 12.44B | |
-7.41% | 11.26B |